Obesity is the result of an imbalance between food intake and energy expenditure resulting in the storing of energy as fat. Adipose tissue contains the largest store of energy in the body and plays important roles in regulating energy partitioning. Developments in genomics, in particular microarray-based expression profiling, have provided scientists with a number of new candidate genes whose expression in adipose tissue is regulated by obesity. Integrating expression profiles with genome-wide linkage and/or association analyses is a promising strategy to identify new genes underlying susceptibility to obesity. This article provides a comprehensive review of adipose-tissue-expressed genes implicated in predisposition to human obesity. The authors consider the following genes of particular interest: peroxisome proliferator-activated receptor gamma and, potentially, INSIG2 acting in adipogenesis; the adrenoreceptors beta 2 and 3, as well as hormone-sensitive lipase acting on lipolysis; uncoupling protein 2 acting in mitochondria energy expenditure; and among secreted molecules the cytokine tumor necrosis factor alpha and the hormone leptin. With the rapid development in genome research, we predict that additional alleles in genes regulating adipose tissue function will be established as risk factors for common obesity in the coming years. This has important implications for the prevention of obesity and may also offer new therapeutic targets.
Introduction
Obesity is the result of an imbalance between food intake and energy expenditure resulting in the storing of energy as fat, primarily in adipose tissue. Genetic epidemiological studies and multiple genome-wide linkage analyses have established that the causes of common obesity are complex involving a Westernized lifestyle in the presence of genetic predisposition. Available results from the study of obesity as well as other disorders with a complex aetiology support that alleles in a number of genes contribute to obesity. To what extent these are common alleles with a small to modest impact on disease, or rare alleles with more measurable effects on a given susceptibility background is uncertain. 1 The obese phenotype results from alterations in numerous metabolic pathways involving several organs, as well as neuronal control of peripheral tissue. We here provide a comprehensive review of adipose-tissue-expressed genes implicated in predisposition to human obesity, and briefly describe modern approaches for identifying such alleles. 2 
Modern approaches to discover adipose tissue genes contributing to obesity
It is an attractive hypothesis that some genes contributing to obesity are expressed in the organ most affected, that is adipose tissue. 3 Up to now, primarily genes with an established function in adipocytes in experimental models have been analysed for allelic association with obesity. Developments in genomics, in particular expression profiling with cDNA or in situ synthesized oligonucleotide microarrays allowing parallel quantification of thousands of different transcripts, have provided scientists with a number of new candidate genes whose expression in adipose tissue is regulated by obesity or weight change. One such identified obesity candidate gene is CIDEA. 4, 5 Of course, there are limits to the usefulness of the microarray approach for identifying adipose genes of importance for obesity. For genes differentially expressed between case and control cohorts, we cannot differentiate between what is primary cause and what is secondary association; one consistent finding is upregulation of inflammatory genes in adipose tissue of obese humans, which intuitively is of greater importance for the metabolic complications of obesity than for obesity per se. 6 Furthermore, disease may be associated with subtle differences in expression of individual genes that are difficult to detect with the traditional microarray technique.
Besides transcript profiling, development of other techniques allows quantification of an increasing number of proteins and metabolites in parallel, thereby highlighting additional candidate genes and pathways for obesity. 7, 8 It will be a challenge to develop powerful tools that can combine data of different origin. 9 In genetics, increasingly efficient genotyping platforms permit not just candidate gene, but genome-wide, association analyses in unrelated case and control cohorts. It is estimated that it is necessary to genotype around 500 000-800 000 polymorphisms/subject to get proper genome coverage. 10 An advantage with association versus linkage is that it is easier to collect cohorts of unrelated obese and lean subjects than to obtain suitable families, although the effects of modest population stratification between cohorts remain an unresolved issue. 11 As for linkage analyses, very large cohorts are necessary to obtain sufficient power to unambiguously show association between alleles and obesity. 10 Integrating expression profiles from relevant tissue with genome-wide linkage and/or association analyses is a novel strategy to increase the efficiency in the difficult task of identifying genes underlying complex traits such as obesity. Up to now, this approach, which requires gene expression profiles and genetic data from a large number of subjects, has primarily been employed in experimental models. Experimental animals have the advantage that expression profiles can easily be obtained from the same large cohort that is used for genetic mapping. For example, by combining mapping of adiposity phenotypes with liver expression profiles in an F2 intercross, Zfp90, C3ar1 and Tgfbr2 were identified as causal for obesity. 12 From such studies, it is clear that some expression quantitative trait loci (QTLs), that is genetic loci regulating specific gene expression, colocalize with disease QTLs supporting that differentially expressed genes are causal for disease. 13 Schadt et al. 13 have concluded that genes whose expression levels significantly correlate with a complex phenotype, transcript abundance are controlled by QTLs co-localizing with phenotypic QTLs and physical location are supported by phenotypic and expression QTLs are natural causal candidates for disease. In analysis of human complex disease, it is difficult to obtain tissue samples from the same subjects who are included in the genetic studies. However, examining genes, whose expression is regulated by the investigated phenotype and chromosomal localization overlap with susceptibility gene loci, is definitely a promising approach.
Adipose tissue genes in human obesity
Below, adipose tissue genes implicated in obesity will be discussed in their specific biological context (Table 1) . A number of adipocyte events could be subjected to genetic modification causing obesity (Figure 1 ).
Adipogenesis.
It has been shown in human in vitro studies that there is a capacity for adipocyte differentiation throughout life, indicating a continuous formation of fat cells.
14 Lipid turnover. 495% of the fat cell volume is composed of lipids, which constantly are turned over owing to new synthesis and breakdown (lipolysis).
15
Mitochondria respiratory function. Although brown fat, which displays high fatty acid oxidation, is sparse in adult humans, it is possible to demonstrate some in vivo function of such adipocytes in adulthood by, for example, treatment with the so-called 'beta 3-agonists'. In addition, the mitochondria of white fat cells have recently been recognized to be more important than considered before. 16 Endocrine/autocrine function. Fat cells secrete a number of hormones, enzymes and inflammatory mediators that control peripheral organs and the brain, as well as adipose tissue function in an autocrine fashion. In addition, nonadipose cells in the stromal or microvascular compartment within adipose tissue may signal to the fat cells.
Exploring the obesity genetics literature reveals a large number of incongruous allelic associations. Initial reported associations with obesity are not confirmed in subsequent studies involving new patient materials. This can be due to aetiological heterogeneity, the study of different ethnic groups with different allele frequencies 17 or different ascertainment schemes, for example recruiting subjects with Obesity genes in human adipose tissue I Dahlman and P Arner mild or severe obesity. Replicating a previously reported disease-marker association but with the risk allele reversed from the previous report, that is flip-flop associations, can occur when the investigated variant is correlated, through interactive effects or linkage disequilibrium, with a causal variant at another locus. 18 However, incongruous allelic associations may also be due to underpowered studies and underestimation of the multiple tests intrinsic in allelic association analyses of complex disorders. In small samples, allelic associations can be observed by chance at the same time as true associations between trait and disease may not be detected. Furthermore, most association studies have analysed one or a few single-nucleotide polymorphisms (SNPs) per gene, which may prevent detection of allelic differences between populations, as well as causal association between gene and disease. At the moment, there is a development towards more comprehensive allelic-association studies of individual genes. Genotyping polymorphisms that cover all variations in the genes in samples comprising several thousand carefully selected and phenotyped subjects is expected to lead to more conclusive results regarding the role of individual genes in obesity. The consequence of the above is that the majority of adipose tissue genes discussed below remains candidates of potential relevance for common human obesity. We primarily refer to the initial studies reporting or negating association between a specific gene allele and obesity, comprehensive studies of individual genes, results raising hypothesis that a particular gene is involved in obesity, as well as review articles, but have been required to leave out a number of association studies owing to space limitation.
Adipogenesis
The transcription factor peroxisome proliferator-activated receptor gamma (PPARG) acts as a master regulator of fat cell function by orchestrating differentiation of new adipocytes and by inducing expression of genes promoting uptake of fatty acids, triglyceride (TAG) synthesis and insulin sensitivity. 19 In humans, dominant negative mutations in the ligand-binding domain of the PPARG gene cause partial lipodystrophy supporting a role of PPARG in fat accumulation in adipose tissue. 20 These mutations in addition cause severe insulin resistance, which has been linked to the inability of adipose tissue to trap and store free fatty acids. 20 By contrast, a gain-of-function mutation in PPARG has been detected in four unrelated individuals with extreme obesity. 21 However, this result is unconfirmed and a fifth identified subject with the mutation displayed only modestly elevated body mass index (BMI), which complicates the interpretation of this mutation in obesity. 22 PPARG exists in three isoforms differing in their 5 0 sequence. PPARG2 is the most abundant isoform in human adipose tissue and it is the only isoform that is exclusively expressed in this organ. 23 BMI has been reported to increase, or to have no impact on, PPARG expression in subcutaneous adipose tissue. [23] [24] [25] A common coding gene variant, Pro12A-la located in the 5 0 -region specific for PPARG2, is according to a meta-analysis of 40 data sets comprising approximately 19 000 subjects associated with higher BMI in the overweight and obese subset (BMI427 kg/m 2 ). 26 The disparate effects of the Pro12Ala polymorphism on BMI in obese and lean individuals suggest that this genetic variant interacts with other factors, which is consistent with reports that the impact of Pro12Ala on obesity can be modified by fatty acid intake. 27 An interaction with lifestyle is also supported by a Finnish study in which overweight subjects were randomly allocated to a control or lifestyle intervention programme, and subjects in the intervention group with the Ala12Ala genotype of PPARG lost more weight. 28 Considering that PPARG promotes lipid storage, it is surprising that the obesity-associated Ala12 allele exhibits reduced DNA binding and transactivation in vitro. 29 Several explanations for these seemingly contradictionary results for the Ala12 allele are possible; there may be compensatory or different pathways by which PPARG regulates obesity, or Ala12 could be in strong linkage disequilibrium with another allele predisposing to obesity. 20 Another hypothesis is that the Pro12 allele protects against obesity-predisposing effects of other genes. PPARG C1431T is a silent polymorphism in the coding region, displaying tight linkage disequilibrium with Pro12A-la. 20 The T1431 allele has been associated with increased BMI, but it is unclear whether the association is independent of Pro12Ala. 27 The transcription factor Sterol regulatory element-binding protein (SREBP) 1c stimulates expression of genes, including 35 In addition, one haplotype in the SREBP1 gene has been associated with morbid obesity, type 2 diabetes (T2DM) and dyslipidemia in French Caucasian cohorts. 36 This haplotype carries SNPs in the 5 0 untranslated region that could affect mRNA and protein levels.
Lamin A/C (LMNA) is an element of the nuclear lamina. Mutation in this gene leading to accumulation of LMNA precursor is one cause of partial lipodystrophy, indicating a role in human adipogenesis. 37 The LMNA precursor interacts with SREBP1, thereby decreasing the pool of active SREBP-1c that normally promotes pre-adipocyte differentiation. 37 A silent allele, 1908T, in LMNA is associated with obesity in two populations. 38, 39 Recently, other genes that infer with adipocyte differentiation have emerged as candidates for obesity. The transcription factor Forkhead box C2 (FOXC2) blocks adipogenesis and protects against adiposity in experimental animals. 40, 41 One SNP in the putative FOXC2 promoter has been associated with susceptibility to, as well as protection against, obesity.
42, 43 No function has been ascribed to this SNP, and human adipose tissue FOXC2 expression is not associated with obesity, leaving us with limited support for an impact of this gene on obesity. 44 The Kruppel-like zincfinger transcription factor KLF2 is a negative regulator of adipocyte differentiation. 45 Common KLF2 polymorphisms are not associated with obesity in a population-based sample composed of 1155 French individuals. 46 Transgenic mice with adipose-tissue-specific overexpression of Wingless-type MMTV integration site family, member 10B (WNT10B) display a 50% reduction in body fat. 47 Christodoulides et al. 48 have identified one proband with early onset obesity, who is heterozygous for a WNT10 C256Y mutation, which blocks adipogenesis. All relatives of the proband who carries this allele are either overweight or obese, whereas it has not been found in 600 control alleles. Lipin acts upstream of PPARG in adipocyte differentiation and promotes fat storage and obesity in the mouse. Human adipose tissue expression of lipin has recently been shown to correlate inversely with obesity and insulin resistance, and positively with glucose transport in adipocytes. 49, 50 One intronic SNP associates with obesity in Finns. 49 The impact of the lipin gene on obesity should be investigated in additional populations before any definitive conclusions can be made regarding the impact of this gene on obesity.
Pathways controlling lipid storage in adipocytes
Lipid storage in adipocytes is governed by the balance between TAG syntheses and lipolysis with subsequent fatty acid release. Diacylglycerol acyltransferase (DGAT) catalyses the synthesis of TAG. The DGAT T79C C allele is associated with increased promoter activity and higher BMI in Turkish women. 51 However, this has not been confirmed in a large French cohort. 52 Other genes involved in TAG storage such as lipoprotein lipase (LPL), acylation stimulating protein (ASP) and fatty acid binding proteins (FABPs) are not implicated in susceptibility to obesity. 15, 53 During lipolysis, TAGs are broken down in a stepwise fashion to free fatty acids (FFA) and glycerol. In humans, lipolysis is modulated by the sympathetic nervous system, insulin and atrial natriuretic peptide (ANP), 54 and is markedly influenced by fat depot, sex and adiposity. 15 Catecholamines act through stimulatory beta 1 (ADRB1), beta 2 (ADRB2) and beta 3 (ADRB3) adrenoreceptors or inhibitory alpha 2 (ADRA2) adrenoreceptors. 15 Non-synonymous ADRB2 polymorphisms that affect receptor function in vitro have been associated with lipolysis and levels of circulating FFA (Arg16Gly), as well as obesity (Arg16Gly and Gln27Glu), although this has not been confirmed in all subsequent studies. [55] [56] [57] [58] [59] [60] In Japanese overweight men, the ADRB2 Gly16 allele predicts rebound weight gain and the Glu27 allele resistance to weight loss following a weight loss programme with diet and exercise. 61 More recently, specific ADRB2 gene haplotypes have been associated with receptor expression, in vitro sensitivity to catecholamine-stimulated lipolysis and obesity.
62-64
A non-synonymous polymorphism, Trp64Arg, in ADRB3 has been reported to be associated with weight gain among obese in a cohort of morbidly obese and non-obese French, and in some studies with obesity. [65] [66] [67] [68] [69] [70] Furthermore, Trp64Arg has been associated with reduced basal metabolic rate and decreased lipolytic sensitivity to an ADRB3-specific ligand, which could explain an impact on adiposity. 65, 66, 70, 71 In the ADRB1 gene, the Gly389Arg 389Arg allele, which affects coupling of the receptor to downstream targets, has been associated with obesity. 72, 73 Surprisingly, this polymorphism has no apparent impact on fat cell lipolysis in vitro. 74 Another
Obesity genes in human adipose tissue I Dahlman and P Arner ADRB1 polymorphism, Ser49Gly, affects agonist-promoted receptor downregulation. 75 Ser49Gly, but not Gly389Arg, predicts long-term changes in body weight. 76 Beta adrenoreceptors signal via G-stimulatory proteins. 15 A polymorphism in exon 10 of the gene that encodes the beta 3 subunit of heterodimeric G-proteins (GB3), C825T, regulates protein levels and splicing. 77 The 825T allele displays enhanced signalling, but reduced catecholamine-induced lipolysis. 77, 78 This allele is associated with obesity in several, but not all, studied populations. [78] [79] [80] [81] [82] TAGs are hydolysed to diglycerides and monoglycerides by hormone-sensitive lipase (HSL) and the recently described adipose triglyceride lipase (ATGL). 15, 83 In humans, HSL is the major lipase for catecholamine-and natriuretic peptidestimulated lipolysis. 83 Decreased adipocyte HSL activity and expression have been observed in obese subjects, in agreement with reduced catecholamine-induced lipolysis in this group. [83] [84] [85] The HSL promoter SNP, À60C4G, regulates gene expression in vitro. 86 This SNP has been reported to have opposite effect on adiposity in different populations.
87-89
The contradictionary results may be explained by different ethnicity of analysed cohorts, different ascertainment criteria, as well as different analysed obesity phenotypes. Furthermore, one allele of an intronic repeat in the HSL gene has been reported to be associated with impaired adipocyte lipolysis, obesity and T2DM. [90] [91] [92] The in vivo importance of ATGL in fat tissue is uncertain. 93 ATGL mRNA levels are unaffected by obesity and adipose tissue lipase activity. 93 Recently, several ATGL SNPs have been associated with the risk of T2DM and the levels of circulating lipids, but not with obesity.
94
Adiponutrin (ADPN) is a protein expressed at high levels in human adipose tissue and displaying triacylglycerol lipase activity. 95, 96 Obese subjects have been reported to have either increased or unchanged levels of abdominal adipose tissue ADPN mRNA levels. 95, 97 Two ADPN intronic polymorphisms are associated with obesity. 97 Carriers of the obesity-associated variants display a lower increase in levels of adipose tissue ADPN mRNA and increased basal lipolysis compared to non-carriers. 97 Perilipin (PLIN) is a phosphoprotein that coats the surface of intracellular lipid droplets in adipocytes and protects them against hydrolysis. PLIN expression is increased in the adipose tissue of obese subjects. 98 One intronic PLIN SNP is associated with mRNA levels and lipolysis, rs891460 A/G in intron 6. 99 Additional intronic SNPs in the PLIN gene in women have been reported to be associated with obesity phenotypes. 100, 101 Furthermore, PLIN 11482A carriers are resistant to weight loss following low-energy diets.
102
The mitochondrion and respiratory function in adipose tissue
Animal models have highlighted adipose tissue mitochondria and energy expenditure as risk factors for obesity. 16 Uncoupling protein 1 (UCP1), 2 (UCP2) and 3 (UCP3) are mitochondria membrane transporters that are involved in dissipating the proton electrochemical gradient, thereby releasing stored energy as heat. [103] [104] [105] This implies a role for UCPs in energy expenditure and adiposity. UCP1 mRNA has been detected at low levels in human white adipose tissue and reported to be decreased in intra-abdominal adipose tissue of obese subjects. 106 The G allele at the UCP1 gene promoter SNP, A-3826G, has been associated with reduced gene expression and weight gain, but the latter has not been confirmed by other investigators. [107] [108] [109] [110] Whereas UCP2 is widely expressed, UCP3 is restricted to skeletal muscle and adipose tissue. 111 Visceral fat UCP2 expression is decreased in obese subjects. 112 Otherwise, expression of these genes displays no major dependence on BMI, but both are increased in individuals undergoing fasting, suggesting a role in metabolic adaptation to fasting. 111 An SNP at position À866 in the UCP2 promoter that affects mRNA expression in vitro is associated with mRNA levels in visceral fat, obesity, as well as 24-h energy expenditure. 113 123 The UCP3 intronic repeat has been reported to be associated with fat loss following 20 weeks of training, 124 whereas the promoter SNP does not regulate weight change.
119
PPARG coactivator 1A (PGC1A) is a transcriptional coregulator that promotes mitochondria biogenesis and expression of enzymes in the respiratory chain. 125 PGC1A is expressed at low levels in human adipose tissue and mRNA levels are reduced in morbid obesity. 126, 127 SNPs in the PGC1A gene have been reported to be associated with obesity in Austrian women. 128 PPARG coactivator 1B (PGC1B) is a recently discovered homologue of PGC1A, which, like PGC1A, in experimental animals induces expression of genes involved in oxidative phosphorylation. 129, 130 PGC1B expression in human adipose tissue relative to obesity has to our knowledge not been investigated. One coding PGC1B SNP, Ala203Pro, has in a Danish population been reported to protect against obesity. 131 It has been shown in experimental model mice that PGC1-induced expression of genes in the mitochondria respiratory chain is partly mediated by the estrogen-related receptor alpha (ESRRA). 132 A polymorphism in the 5 0 -flanking region of the ESRRA gene has been associated with obesity in a Japanese population. 133 A recently discovered adipocyte-expressed candidate gene for obesity is cell death-inducing DFFA-like effector A (CIDEA). Although the molecular function of CIDEA is unknown, available data are compatible with an impact on Obesity genes in human adipose tissue I Dahlman and P Arner mitochondria respiratory function and lipolysis. 134, 135 Adipose tissue CIDEA levels are reduced in obese humans and one non-synonymous SNP has been associated with obesity in female and male Swedes.
5,135
Insulin signalling in adipocytes
Insulin stimulates the build-up of lipid stores in adipose tissue and an insulin gene variable number of tandem repeat is associated with juvenile obesity, implying a role for genes participating in insulin signalling in genetic susceptibility to obesity. 15, 136 Polymorphisms in the insulin receptor (INSR) or insulin receptor substrate genes do not seem to affect human adiposity. 137 Sorbin and SH3-domain-containing-1 (SORBS1) is the human homologue of c-Cbl associated protein, which is highly expressed in adipocytes and through interaction with the INSR regulates glucose uptake. 138 A non-synonymous SORBS1 SNP, Thr228Ala in exon 7, has been associated with obesity and T2DM. 139 Mice deficient in the alpha(2)-Heremans-Schmid glycoprotein (AHSG) gene, which inhibits insulin-induced INSR autophosphorylation and tyrosine kinase activity in vitro, display improved insulin sensitivity and resistance to weight gain. 140 SNPs in the human AHSG gene have been reported to be associated with adipocyte insulin action, obesity and T2DM. [141] [142] [143] Ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) is an inhibitor of insulin-receptor tyrosine kinase. One ENPP1 haplotype is associated with childhood and morbid obesity, T2DM, as well as circulating levels of ENPP1. [144] [145] [146] Expression of a long ENPP1 mRNA isoform, which includes one of the SNPs defining the risk haplotype, is specific for pancreatic islet beta cells, adipocytes and liver. 144 In addition, one ENPP1 SNP may impair insulin binding to the insulin receptor. 144 Two recent reports including several thousand subjects of European ancestry have not confirmed association between the ENPP1 haplotype and obesity or T2DM. 147, 148 The reasons for the failure to confirm association may be the same as that for HSL, see above. In an extensive genetic study of weight reduction including 648 obese subjects who underwent intervention with hypoenergetic diet, ENPP1 was nominally associated with weight loss.
149
Endocrine and paracrine action of adipocytes
Human adipose tissue secrete hormones, cytokines and other molecules, together termed 'adipokines', which besides having local effects through release into the circulation participate in the regulation of whole body metabolism. The best characterized obesity gene, leptin, encodes a peptide hormone secreted exclusively by adipocytes. 150, 151 Leptin primarily acts on appetite regulation in the CNS but in addition has peripheral effects. Mutation in the leptin gene is a rare cause of severe monogenic obesity. 150, 151 Common obesity is associated with leptin resistance and increased circulating leptin levels. 150 A common A4G 5 0 UTR variant in the leptin gene has been associated with leptin levels and obesity. 152, 153 In the 5 0 region, GÀ2548A has been associated with response to low calorie diet, obesity and leptin levels. [153] [154] [155] [156] [157] Furthermore, a leptin gene 3 0 -tetranucleotide repeat is associated with BMI. 158 Finally, in the most extensive study of leptin gene polymorphisms in common obesity, common variants further upstream in the 5 0 region have displayed association with BMI. 159 Adiponectin (APM1) is another hormone exclusively expressed in differentiated adipocytes, strongly implicated as a regulator of insulin sensitivity but also as a candidate for obesity.
150 APM1 expression is reduced in human obesity and insulin-resistant states, and upregulated following weight loss. 150 Several studies have analysed common APM1 polymorphisms in disease. The common þ 45T4G and þ 276G4T variants have been associated with circulating levels of APM1, obesity and T2DM, but with inconsistent results between different cohorts. 160 APM1 signals through adiponectin receptors 1 (ADIPOR1) and 2 (ADIPOR2).
150
ADIPOR1 is the common receptor in subcutaneous adipocytes and its expression is downregulated in obese subjects. 161 ADIPOR1 and ADIPOR2 SNPs have been associated with T2DM, but not with obesity. 162, 163 Plasminogen activator inhibitor (PAI-1) is a regulator of the fibrinolytic system primarily implicated in ischaemic heart disease. Mice deficient in PAI-1 are resistant to dietinduced obesity. 164 Human adipose tissue secretion of PAI-1 is increased in obesity. 165 One functional promoter SNP in the PAI-1 gene has been associated with obesity but this has not been confirmed by others. 166, 167 Human obesity is associated with macrophage infiltration in adipose tissue and enhanced adipose tissue expression of proinflammatory mediators, including tumour necrosis factor alpha (TNFA), monocyte chemoattractant protein 1 (MCP-1) and interleukin 6 (IL6) that may contribute to insulin resistance. 6, 168, 169 TNFA has been shown to increase lipolysis in human adipocytes. 15 The TNFA locus has been linked to obesity. 170 One TNFA promoter SNP at position À308 that influences gene transcription has in a recent metaanalysis been associated with a modest increased risk of developing obesity, OR 1.23. 171, 172 The C allele of one polymorphism in the IL6 promoter, ÀG174C, has in different populations been associated with obesity and decreased risk of T2DM. [173] [174] [175] [176] The C allele results in lower IL6 expression. 177 Furthermore, the CÀ174C genotype has been associated with lower energy expenditure and lower rate of whole-body glucose uptake. 178 Another IL6 polymorphism, a CA repeat, has in two independent populations been reported to be associated with obesity. 179 Furthermore, polymorphisms in the IL6 receptor (IL6R) have been reported to be associated with obesity in Pima Indians and a Spanish population. 180, 181 The ÀA2518G polymorphism in the distal regulatory region of MCP1 is associated with circulating MCP1 levels, insulinsensitive and T2DM, but not with obesity. 182 Obesity genes in human adipose tissue I Dahlman and P Arner
Adipose-tissue-infiltrating macrophages are the source of secreted resistin, which in experimental models is implicated in insulin resistance. 150 Adipose tissue expression of resistin is increased in human obese subjects. 183 One resistin 5 0 -flanking polymorphism, À420C4G, has been analysed for association with obesity with conflicting results. 184, 185 The À420C4G G/G genotype displays significantly increased basal promoter activity in adipocytes, and is associated with significantly higher resistin mRNA levels in human abdominal subcutaneous fat. 186 Furthermore, an ATG repeat in the 3 0 -UTR region of resistin has been associated with insulin resistance, but not with obesity. 187 Visfatin is a recently identified peptide predominantly expressed in visceral adipose tissue and displaying insulinlike effects in experimental models. 188 A correlation between plasma visfatin concentration, visceral visfatin mRNA levels and obesity has been reported. 189 Three polymorphisms covering the common variation in the visfatin gene are not associated with obesity or T2DM in a large cohort of Caucasians. 190 
Conclusions
It is an attractive hypothesis that some obesity genes have a primary role in regulating fat cell function. Although the situation for human obesity candidate genetic studies is the same independent of where the gene is expressed, analyses of adipose-tissue-expressed genes have the practical advantage that it is possible to combine a genetic approach with gene expression and functional assays. Different ethnicity of analysed cohorts, different ascertainment criteria, as well as different analysed obesity phenotypes make it difficult to compare multiple allelic association studies of the same obesity candidate gene and may partially explain the difficulty to confirm reported association between specific gene alleles and obesity. So far, established functions in adipocytes and/or strong evidence of genetic association have implied a handful of adipocyte genes in obesity. In this regard, the authors consider PPARG, INSIG2, ADRB2, ADRB3, HSL, UCP2, leptin and TNFA to be of particular interest ( Table 2 ). The functions of these genes imply that the primary place of action of some alleles predisposing to obesity is in adipocytes by regulating adipogenesis and lipid storage (PPARG, INSIG2), lipolysis (ADRB2, ADRB3, HSL) and energy expenditure (UCP2). TNFA and leptin on the other hand are factors secreted by adipose tissue. In addition, modulators of lipolysis affect levels of circulating FFA, which can act as signalling molecules in metabolism. This suggests that alleles in adipocyte genes via peripheral effects, potentially on energy expenditure or food intake, regulate body weight.
With the rapid development in human genome research, including new tools such as dense whole genome maps of common polymorphisms and high-throughput genotyping platforms allowing complete analysis of genes in large materials of patients and controls, we predict that a number of new susceptibility gene alleles for obesity will be established in the near future. Table 2 Adipose genes with possible influence on common human obesity
Gene
Findings with polymorphism PPARG Meta-analysis suggests linkage between polymorphism and BMI. Obesity associated polymorphism leads to amino acid changes that are functional INSIG2 SNP 10 kb upstream of INSIG2 associated with obesity in three family-based and three samples of unrelated individuals. ADRB2 Association to obesity in many studies. Obesity associated polymorphisms lead to amino acid changes that are functional in transfected cells and in human fat cells (lipolysis) ADRB3 Association to obesity in many studies. The obesity-associated polymorphism leads to amino-acid changes that are functional in transfected cells and in human fat cells (lipolysis) HSL Association to obesity in many studies. Obesity-associated polymorphism is associated with low lipolysis in human fat cells UCP2 Association to obesity in independent samples. The obesity-associated polymorphism in the promoter leads to altered promotor function and influences gene expression in adipose tissue ENPP1
Association to obesity in independent samples. The obesity-associated polymorphism impairs insulin binding to the insulin receptor Leptin Adipocyte-secreted hormone regulating food intake. Several association studies imply polymorphisms in the leptin gene in obesity TNFA Meta-analysis suggests linkage between polymorphism and BMI. The obesity-associated polymorphism in the promoter is functional
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